Bonesupport Holding AB (CHIX:BONEXs) Stock Price, Trades & News

Bonesupport Holding AB is a fast-growing ortho-biologics company that focuses on the treatment of bone disorders. The Company develops and commercializes injectable bio-ceramic bone graft substitutes based on its CERAMENT platform, which remodels to bone and can release pharmaceuticals to promote healing. The products of the company focus on trauma, revision arthroplasty (replacement of joint prostheses), chronic osteomyelitis (bone infection), and foot and ankle surgery. The Group manages and monitors operations in two operating segments: United States and Europe & Rest of the World (EUROW).

Financial Strength

10/10

Name	Current	Vs Industry
Cash-To-Debt	32.28
Equity-to-Asset	0.84
Debt-to-Equity	0.02
Debt-to-EBITDA	0.05
Interest Coverage	12.99
Piotroski F-Score	7/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	50.88	Distress Grey Safe
Beneish M-Score	-2.72	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

9/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	51.1
	3-Year Book Growth Rate	46.7
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	68.85
	Future 3-5Y Total Revenue Growth Rate Estimate	28.47

Momentum Rank

7/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	57.39
	9-Day RSI	58.7
	14-Day RSI	58.3
	3-1 Month Momentum %	20.81
	6-1 Month Momentum %	21.39
	12-1 Month Momentum %	-18.58

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	5.13
	Quick Ratio	4.23
	Cash Ratio	2.62
	Days Inventory	552.69
	Days Sales Outstanding	60.55
	Days Payable	71.72

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-0.7
	Shareholder Yield %	0.01

Profitability Rank

4/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	92.48
	Operating Margin %	22.56
	Net Margin %	15.23
	EBITDA Margin %	23.23
	FCF Margin %	20.12
	OCF Margin %	20.54
	ROE %	22.14
	ROA %	18.45
	ROIC %	31.99
	3-Year ROIIC %	55.81
	ROC (Joel Greenblatt) %	106.42
	ROCE %	32.58
	Years of Profitability over Past 10-Year	3
	Moat Score	4
	Tariff Resilience Score	5

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	81.08
	Forward PE Ratio	47.93
	PE Ratio without NRI	81.08
	Price-to-Owner-Earnings	104.86
	PS Ratio	12.34
	PB Ratio	15.75
	Price-to-Tangible-Book	16.01
	Price-to-Free-Cash-Flow	61.33
	Price-to-Operating-Cash-Flow	60.09
	EV-to-EBIT	51.89
	EV-to-EBITDA	50.4
	EV-to-Revenue	11.71
	EV-to-FCF	58.35
	Price-to-GF-Value	0.55
	Price-to-Projected-FCF	15.69
	Price-to-Graham-Number	7.6
	Price-to-Net-Current-Asset-Value	20.82
	Price-to-Net-Cash	53.77
	Earnings Yield (Greenblatt) %	1.92
	FCF Yield %	1.66

Financials (Next Earnings Date:2026-07-16)

Annual Quarterly TTM

CHIX:BONEXs's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Bonesupport Holding AB Executives

Details

GF Value™: kr417.39

CHIX:BONEXs

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with BONEXs. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil kr)	1,215.14
	EPS (TTM) (kr)	2.77
	Beta	0.6112
	3-Year Sharpe Ratio	0.6
	3-Year Sortino Ratio	1.07
	Volatility %	41.83
	14-Day RSI	58.3
	14-Day ATR (kr)	0.483985
	20-Day SMA (kr)	229.6
	12-1 Month Momentum %	-18.58
	52-Week Range (kr)	175.6 - 339.9
	Shares Outstanding (Mil)	65.49

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	7
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Bonesupport Holding AB Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Bonesupport Holding AB Stock Events

Financials Calendars

Event	Date	Price (kr)
Third quarter earnings conference call for 2026	2026-10-22	In 105 days
Third quarter earnings results for 2026	2026-10-22	In 105 days
Second quarter earnings conference call for 2026	2026-07-16 10:00	In 8 days
Second quarter earnings results for 2026	2026-07-16 08:00	In 8 days
General meeting for 2026	2026-05-12 10:00	218.30 (+0.00%)
First quarter earnings conference call for 2026	2026-04-22 10:00	257.80 (-1.49%)
First quarter earnings results for 2026	2026-04-22 08:00	257.80 (-1.49%)
Annual report for 2025	2026-04-16	190.05 (+0.00%)
Fourth quarter earnings conference call for 2025	2026-02-24 10:00	180.80 (+0.00%)
Fourth quarter earnings results for 2025	2026-02-24 08:00	180.80 (+0.00%)

Show

Entries

Bonesupport Holding AB Frequently Asked Questions

What is Bonesupport Holding AB(CHIX:BONEXs)'s stock price today?

The current price of CHIX:BONEXs is kr229.60. The 52 week high of CHIX:BONEXs is kr339.90 and 52 week low is kr175.60.

When is next earnings date of Bonesupport Holding AB(CHIX:BONEXs)?

The next earnings date of Bonesupport Holding AB(CHIX:BONEXs) is 2026-07-16.

Does Bonesupport Holding AB(CHIX:BONEXs) pay dividends? If so, how much?

Bonesupport Holding AB(CHIX:BONEXs) does not pay dividend.

Press Release

	Subject	Date
	MCRA Assists BONESUPPORT AB with the First Ever Combination Product DeNovo Decision Granted by the U.S. FDA	2022-07-06
	MCRA Assists BONESUPPORT AB with the First Ever Combination Product DeNovo Decision Granted by the U.S. FDA	2022-06-26
	MCRA Assists BONESUPPORT AB with the First Ever Combination Product DeNovo Decision Granted by the U.S. FDA	2022-06-16
	BONESUPPORT Appoints Michael Roth as General Manager & Executive Vice President Commercial Operations North America	2020-04-29

10/Page

Articles on Bonesupport Holding AB

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.